Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

First International Summit on Interventional Pharmacoeconomics

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Opportunities to Optimize Cancer Policies Panel Discussion

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Jun

Today In Oncology

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Opportunities to Optimize Cancer Policies Panel Discussion

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Subgroup Analysis Demonstrates Efficacy of Inavolisib Regimen in Asian Patients With Advanced Breast Cancer

GLP-1 Receptor Agonists Linked to Lower Colorectal Cancer Risk in Patients With IBD

Chinese Study of HER2-Targeted Combination Therapy for Locally Advanced Breast Cancer

Multi-Cancer Early Detection Test Performs Well in Real-World Asian Cohort

Early Palliative Care Improves Quality of Life for Patients With Breast Cancer in India